Loading...
XNASOCX
Market cap39mUSD
Jan 06, Last price  
2.29USD
1D
1.72%
1Q
-17.99%
Jan 2017
-66.38%
IPO
-62.08%
Name

OncoCyte Corp

Chart & Performance

D1W1MN
XNAS:OCX chart
P/E
—
P/S
25.65
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
32.23%
Rev. gr., 5y
0.00%
Revenues
2m
+56.89%
00000001,216,0007,727,000958,0001,503,000
Net income
-28m
L-62.17%
-3,495,000-4,986,000-8,735,000-11,168,000-19,375,000-15,754,000-22,329,000-29,932,000-64,097,000-73,440,000-27,781,000
CFO
-23m
L-48.81%
-710,000-1,164,000-4,229,000-7,522,000-13,385,000-11,649,000-19,715,000-25,980,000-35,941,000-45,568,000-23,325,000
Earnings
May 13, 2025

Profile

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
URL
https://oncocyte.com/
IPO date
Dec 30, 2015
Employees
75
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,503
56.89%
958
-87.60%
Cost of revenue
23,920
31,290
Unusual Expense (Income)
NOPBT
(22,417)
(30,332)
NOPBT Margin
Operating Taxes
54,828
Tax Rate
NOPAT
(22,417)
(85,160)
Net income
(27,781)
-62.17%
(73,440)
14.58%
Dividends
Dividend yield
Proceeds from repurchase of equity
12,730
37,236
BB yield
-66.55%
-2,094.52%
Debt
Debt current
1,330
815
Long-term debt
5,073
6,273
Deferred revenue
Other long-term liabilities
39,900
50,964
Net debt
(3,029)
(15,038)
Cash flow
Cash from operating activities
(23,325)
(45,568)
CAPEX
(281)
(4,340)
Cash from investing activities
(932)
(4,340)
Cash from financing activities
12,186
35,806
FCF
(17,002)
(87,484)
Balance
Cash
9,432
20,426
Long term investments
1,700
Excess cash
9,357
22,078
Stockholders' equity
25,594
39,594
Invested Capital
59,671
66,722
ROIC
ROCE
EV
Common stock shares outstanding
7,651
5,540
Price
2.50
679.06%
0.32
-85.21%
Market cap
19,128
975.92%
1,778
-81.57%
EV
21,224
(7,958)
EBITDA
(20,737)
(25,112)
EV/EBITDA
0.32
Interest
52
77
Interest/NOPBT